Bacterial Pneumonia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major bacterial pneumonia markets reached a value of US$ 2.0 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 3.6 Billion by 2034, exhibiting a growth rate (CAGR) of 5.44% during 2024-2034.
The bacterial pneumonia market has been comprehensively analyzed in IMARC's new report titled "Bacterial Pneumonia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Bacterial pneumonia refers to a type of lung infection caused by bacteria. It occurs when bacteria enter the respiratory system and multiply, leading to inflammation and infection in the air sacs (alveoli) of the lungs. This condition results in an accumulation of fluid and pus, impairing oxygen exchange and causing several indications. The common symptoms associated with the illness include cough, chills, fever, difficulty breathing or shortness of breath, fatigue, weakness, the production of thick, discolored phlegm, an increased heart rate, etc. Individuals suffering from this ailment may also experience chest pain that progresses with coughing or deep breathing. The diagnosis of bacterial pneumonia usually involves a physical examination, clinical features evaluation, and medical history review. During a physical exam, the healthcare provider will utilize a stethoscope to check for irregular breath sounds, such as crackles or wheezing. Furthermore, a chest X-ray is recommended to detect abnormalities in the lungs, which are indicative of infection. Numerous other investigations, including pulse oximetry, arterial blood gas analysis, computed tomography scans, etc., are also performed to confirm a diagnosis among patients.
The increasing cases of respiratory tract infections, including the flu or common cold, that cause inflammation and damage to the inner lining, making it easier for bacteria to invade the lungs, are primarily driving the bacterial pneumonia market. In addition to this, the growing geriatric population, who have weaker immune systems along with certain underlying health conditions, is also creating a positive outlook for the market. Moreover, the widespread adoption of effective medications, such as antibiotics, bronchodilators, antipyretics, etc., to reduce the symptoms of the ailment is further bolstering the market growth. Apart from this, the escalating utilization of chest physiotherapy techniques, which help to loosen and mobilize secretions in the lungs, thereby facilitating their removal and improving pulmonary functions in patients, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of respiratory therapies, like nebulization and inhalation, owing to their several advantages, including targeted drug delivery and enhanced absorption of medications into the bloodstream, is expected to drive the bacterial pneumonia market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the bacterial pneumonia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for bacterial pneumonia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the bacterial pneumonia market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the bacterial pneumonia market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the bacterial pneumonia market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current bacterial pneumonia marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug overview
Mechanism of action
Regulatory status
Clinical trial results
Drug uptake and market performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the bacterial pneumonia market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the bacterial pneumonia market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the bacterial pneumonia market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of bacterial pneumonia across the seven major markets?
What is the number of prevalent cases (2018-2034) of bacterial pneumonia by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of bacterial pneumonia by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with bacterial pneumonia across the seven major markets?
What is the size of the bacterial pneumonia patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of bacterial pneumonia?
What will be the growth rate of patients across the seven major markets?
Bacterial Pneumonia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for bacterial pneumonia drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the bacterial pneumonia market?
What are the key regulatory events related to the bacterial pneumonia market?
What is the structure of clinical trial landscape by status related to the bacterial pneumonia market?
What is the structure of clinical trial landscape by phase related to the bacterial pneumonia market?
What is the structure of clinical trial landscape by route of administration related to the bacterial pneumonia market?
The bacterial pneumonia market has been comprehensively analyzed in IMARC's new report titled "Bacterial Pneumonia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Bacterial pneumonia refers to a type of lung infection caused by bacteria. It occurs when bacteria enter the respiratory system and multiply, leading to inflammation and infection in the air sacs (alveoli) of the lungs. This condition results in an accumulation of fluid and pus, impairing oxygen exchange and causing several indications. The common symptoms associated with the illness include cough, chills, fever, difficulty breathing or shortness of breath, fatigue, weakness, the production of thick, discolored phlegm, an increased heart rate, etc. Individuals suffering from this ailment may also experience chest pain that progresses with coughing or deep breathing. The diagnosis of bacterial pneumonia usually involves a physical examination, clinical features evaluation, and medical history review. During a physical exam, the healthcare provider will utilize a stethoscope to check for irregular breath sounds, such as crackles or wheezing. Furthermore, a chest X-ray is recommended to detect abnormalities in the lungs, which are indicative of infection. Numerous other investigations, including pulse oximetry, arterial blood gas analysis, computed tomography scans, etc., are also performed to confirm a diagnosis among patients.
The increasing cases of respiratory tract infections, including the flu or common cold, that cause inflammation and damage to the inner lining, making it easier for bacteria to invade the lungs, are primarily driving the bacterial pneumonia market. In addition to this, the growing geriatric population, who have weaker immune systems along with certain underlying health conditions, is also creating a positive outlook for the market. Moreover, the widespread adoption of effective medications, such as antibiotics, bronchodilators, antipyretics, etc., to reduce the symptoms of the ailment is further bolstering the market growth. Apart from this, the escalating utilization of chest physiotherapy techniques, which help to loosen and mobilize secretions in the lungs, thereby facilitating their removal and improving pulmonary functions in patients, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of respiratory therapies, like nebulization and inhalation, owing to their several advantages, including targeted drug delivery and enhanced absorption of medications into the bloodstream, is expected to drive the bacterial pneumonia market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the bacterial pneumonia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for bacterial pneumonia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the bacterial pneumonia market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the bacterial pneumonia market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the bacterial pneumonia market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current bacterial pneumonia marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug overview
Mechanism of action
Regulatory status
Clinical trial results
Drug uptake and market performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the bacterial pneumonia market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the bacterial pneumonia market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the bacterial pneumonia market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of bacterial pneumonia across the seven major markets?
What is the number of prevalent cases (2018-2034) of bacterial pneumonia by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of bacterial pneumonia by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with bacterial pneumonia across the seven major markets?
What is the size of the bacterial pneumonia patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of bacterial pneumonia?
What will be the growth rate of patients across the seven major markets?
Bacterial Pneumonia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for bacterial pneumonia drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the bacterial pneumonia market?
What are the key regulatory events related to the bacterial pneumonia market?
What is the structure of clinical trial landscape by status related to the bacterial pneumonia market?
What is the structure of clinical trial landscape by phase related to the bacterial pneumonia market?
What is the structure of clinical trial landscape by route of administration related to the bacterial pneumonia market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 BACTERIAL PNEUMONIA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 BACTERIAL PNEUMONIA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 BACTERIAL PNEUMONIA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 BACTERIAL PNEUMONIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 BACTERIAL PNEUMONIA - UNMET NEEDS
10 BACTERIAL PNEUMONIA - KEY ENDPOINTS OF TREATMENT
11 BACTERIAL PNEUMONIA - MARKETED PRODUCTS
11.1 List of Bacterial Pneumonia Marketed Drugs Across the Top 7 Markets
11.1.1 Xacduro (Durlobactam/sulbactam) - Entasis Therapeutics
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Avycaz (Avibactam/ceftazidime) - Allergan/Pfizer
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Fetroja (Cefiderocol) - Shionogi
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Nuzyra (Omadacycline) - Paratek Pharmaceuticals
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Teflaro (Ceftaroline fosamil) - AbbVie/Sumitomo Pharma/Takeda
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 BACTERIAL PNEUMONIA - PIPELINE DRUGS
12.1 List of Bacterial Pneumonia Pipeline Drugs Across the Top 7 Markets
12.1.1 CMTX101 - Clarametyx Biosciences
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 CAL 02 - Eagle Pharmaceuticals
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 AR 105 - Aridis Pharmaceuticals
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. BACTERIAL PNEUMONIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. BACTERIAL PNEUMONIA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 BACTERIAL PNEUMONIA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Bacterial Pneumonia - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Bacterial Pneumonia - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Bacterial Pneumonia - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Bacterial Pneumonia - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Bacterial Pneumonia - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Bacterial Pneumonia - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Bacterial Pneumonia - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Bacterial Pneumonia - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Bacterial Pneumonia - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Bacterial Pneumonia - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Bacterial Pneumonia - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Bacterial Pneumonia - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Bacterial Pneumonia - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Bacterial Pneumonia - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Bacterial Pneumonia - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Bacterial Pneumonia - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Bacterial Pneumonia - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Bacterial Pneumonia - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Bacterial Pneumonia - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Bacterial Pneumonia - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Bacterial Pneumonia - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Bacterial Pneumonia - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Bacterial Pneumonia - Access and Reimbursement Overview
16 BACTERIAL PNEUMONIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 BACTERIAL PNEUMONIA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 BACTERIAL PNEUMONIA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 BACTERIAL PNEUMONIA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 BACTERIAL PNEUMONIA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 BACTERIAL PNEUMONIA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 BACTERIAL PNEUMONIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 BACTERIAL PNEUMONIA - UNMET NEEDS
10 BACTERIAL PNEUMONIA - KEY ENDPOINTS OF TREATMENT
11 BACTERIAL PNEUMONIA - MARKETED PRODUCTS
11.1 List of Bacterial Pneumonia Marketed Drugs Across the Top 7 Markets
11.1.1 Xacduro (Durlobactam/sulbactam) - Entasis Therapeutics
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Avycaz (Avibactam/ceftazidime) - Allergan/Pfizer
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Fetroja (Cefiderocol) - Shionogi
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Nuzyra (Omadacycline) - Paratek Pharmaceuticals
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Teflaro (Ceftaroline fosamil) - AbbVie/Sumitomo Pharma/Takeda
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 BACTERIAL PNEUMONIA - PIPELINE DRUGS
12.1 List of Bacterial Pneumonia Pipeline Drugs Across the Top 7 Markets
12.1.1 CMTX101 - Clarametyx Biosciences
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 CAL 02 - Eagle Pharmaceuticals
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 AR 105 - Aridis Pharmaceuticals
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. BACTERIAL PNEUMONIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. BACTERIAL PNEUMONIA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 BACTERIAL PNEUMONIA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Bacterial Pneumonia - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Bacterial Pneumonia - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Bacterial Pneumonia - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Bacterial Pneumonia - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Bacterial Pneumonia - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Bacterial Pneumonia - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Bacterial Pneumonia - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Bacterial Pneumonia - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Bacterial Pneumonia - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Bacterial Pneumonia - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Bacterial Pneumonia - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Bacterial Pneumonia - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Bacterial Pneumonia - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Bacterial Pneumonia - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Bacterial Pneumonia - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Bacterial Pneumonia - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Bacterial Pneumonia - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Bacterial Pneumonia - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Bacterial Pneumonia - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Bacterial Pneumonia - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Bacterial Pneumonia - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Bacterial Pneumonia - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Bacterial Pneumonia - Access and Reimbursement Overview
16 BACTERIAL PNEUMONIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 BACTERIAL PNEUMONIA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 BACTERIAL PNEUMONIA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
